424 related articles for article (PubMed ID: 26644288)
1. Special AT-rich sequence-binding protein 2 (SATB2) expression is sensitive but may not be specific for osteosarcoma as compared with other high-grade primary bone sarcomas.
Davis JL; Horvai AE
Histopathology; 2016 Jul; 69(1):84-90. PubMed ID: 26644288
[TBL] [Abstract][Full Text] [Related]
2. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours.
Conner JR; Hornick JL
Histopathology; 2013 Jul; 63(1):36-49. PubMed ID: 23701429
[TBL] [Abstract][Full Text] [Related]
3. The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas.
Machado I; Navarro S; Picci P; Llombart-Bosch A
Pathol Res Pract; 2016 Sep; 212(9):811-6. PubMed ID: 27465835
[TBL] [Abstract][Full Text] [Related]
4. [Significance of SATB2 in the pathologic diagnosis of osteosarcoma].
Li M; Cai YP; Lu KY; Chen Y; Zhu X; Yin Y; Tang J
Zhonghua Bing Li Xue Za Zhi; 2016 Sep; 45(9):631-5. PubMed ID: 27646893
[TBL] [Abstract][Full Text] [Related]
5. [Value of MDM2, CDK4 and SATB2 immunohistochemistry in histologic diagnosis of low-grade osteosarcoma].
Chen CY; Zhang HZ; Jiang ZM; Zhou J; Chen J; Liu L
Zhonghua Bing Li Xue Za Zhi; 2016 Jun; 45(6):387-92. PubMed ID: 27256046
[TBL] [Abstract][Full Text] [Related]
6. SATB2 Expression Is Sensitive but Not Specific for Osteosarcomatous Components of Gynecologic Tract Carcinosarcomas: A Clinicopathologic Study of 60 Cases.
Sangoi AR; Kshirsagar M; Horvai AE; Roma AA
Int J Gynecol Pathol; 2017 Mar; 36(2):140-145. PubMed ID: 27294605
[TBL] [Abstract][Full Text] [Related]
7. Osteocalcin and Osteonectin Expression in Canine Osteosarcoma.
Wehrle-Martinez AS; Dittmer KE; Aberdein D; Thompson KG
Vet Pathol; 2016 Jul; 53(4):781-7. PubMed ID: 26926085
[TBL] [Abstract][Full Text] [Related]
8. Expression of SATB2 in primary cutaneous sarcomatoid neoplasms: a potential diagnostic pitfall.
Szczepanski JM; Siddiqui J; Patel RM; Harms PW; Hrycaj SM; Chan MP
Pathology; 2023 Apr; 55(3):350-354. PubMed ID: 36732203
[TBL] [Abstract][Full Text] [Related]
9. SATB2 Expression in Undifferentiated Pleomorphic Sarcomas of Bone.
Warmke LM; Maloney N; Leung CH; Lin H; Lazar AJ; Wang WL
Am J Clin Pathol; 2022 Aug; 158(2):235-241. PubMed ID: 35311957
[TBL] [Abstract][Full Text] [Related]
10. SATB2 is a novel marker of osteoblastic differentiation and colorectal adenocarcinoma.
Ordóñez NG
Adv Anat Pathol; 2014 Jan; 21(1):63-7. PubMed ID: 24316906
[TBL] [Abstract][Full Text] [Related]
11. SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study.
Le Page C; Almadani N; Turashvili G; Bataillon G; Portelance L; Provencher D; Mes-Masson AM; Gilks B; Hoang L; Rahimi K
Int J Gynecol Pathol; 2021 Sep; 40(5):487-494. PubMed ID: 33720083
[TBL] [Abstract][Full Text] [Related]
12. BCOR Overexpression Is a Highly Sensitive Marker in Round Cell Sarcomas With BCOR Genetic Abnormalities.
Kao YC; Sung YS; Zhang L; Jungbluth AA; Huang SC; Argani P; Agaram NP; Zin A; Alaggio R; Antonescu CR
Am J Surg Pathol; 2016 Dec; 40(12):1670-1678. PubMed ID: 27428733
[TBL] [Abstract][Full Text] [Related]
13. Sclerosing epithelioid fibrosarcoma of bone: morphological, immunophenotypical, and molecular findings of 9 cases.
Kosemehmetoglu K; Ardic F; Kilpatrick SE; Aydingoz U; Sumathi VP; Michal M
Virchows Arch; 2021 Apr; 478(4):767-777. PubMed ID: 33084978
[TBL] [Abstract][Full Text] [Related]
14. YJ5 as an immunohistochemical marker of osteogenic lineage.
Chua K; Virshup DM; Odono EG; Chang KTE; Tan NJH; Hue SS; Sim AYL; Lee VKM
Pathology; 2021 Feb; 53(2):229-238. PubMed ID: 33187685
[TBL] [Abstract][Full Text] [Related]
15. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours: comment on Conner et al. (2013).
Creytens D; Ferdinande L
Histopathology; 2015 Aug; 67(2):272-3. PubMed ID: 25469978
[No Abstract] [Full Text] [Related]
16. Primary sclerosing epithelioid fibrosarcoma of bone: analysis of a series.
Wojcik JB; Bellizzi AM; Dal Cin P; Bredella MA; Fletcher CD; Hornicek FJ; Deshpande V; Hornick JL; Nielsen GP
Am J Surg Pathol; 2014 Nov; 38(11):1538-44. PubMed ID: 24921641
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical characterization of appendiceal mucinous neoplasms and the value of special AT-rich sequence-binding protein 2 in their distinction from primary ovarian mucinous tumours.
Strickland S; Parra-Herran C
Histopathology; 2016 Jun; 68(7):977-87. PubMed ID: 26542609
[TBL] [Abstract][Full Text] [Related]
18. SOX9 and SATB2 immunohistochemistry cannot reliably distinguish between osteosarcoma and chondrosarcoma on biopsy material.
Sharma AE; Pytel P; Cipriani NA
Hum Pathol; 2022 Mar; 121():56-64. PubMed ID: 35016891
[TBL] [Abstract][Full Text] [Related]
19. KPNA2 expression is a potential marker for differential diagnosis between osteosarcomas and other malignant bone tumor mimics.
Jiang L; Liu J; Wei Q; Wang Y
Diagn Pathol; 2020 Nov; 15(1):135. PubMed ID: 33176814
[TBL] [Abstract][Full Text] [Related]
20. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone.
Dujardin F; Binh MB; Bouvier C; Gomez-Brouchet A; Larousserie F; Muret Ad; Louis-Brennetot C; Aurias A; Coindre JM; Guillou L; Pedeutour F; Duval H; Collin C; de Pinieux G
Mod Pathol; 2011 May; 24(5):624-37. PubMed ID: 21336260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
